Acute graft versus host disease in skin – European Clinical Trials Information Network

A study testing venetoclax for treating acute graft-versus-host disease in patients who received a stem cell transplant from a donor

Thu, 30 Apr 2026 13:08:22 +0000

This study is looking at acute graft-versus-host disease of the skin, which is a condition that can occur after a person receives a transplant of blood-forming stem cells from a donor. In this condition, the donated cells recognize the recipient’s body as foreign and attack it, particularly affecting the skin. The treatment being tested is Venclyxto, which contains the active ingredient venetoclax. This medication comes as film-coated tablets that are taken by mouth in different strengths: 10 mg, 50 mg, and 100 mg. The purpose of this study is to determine the maximum tolerated dose of venetoclax that can be safely given to patients with this condition.

The study will include patients who are at least 18 years old and have received a stem cell transplant from any type of donor. These patients must have developed acute graft-versus-host disease that requires treatment with immune-suppressing medicines such as prednisone. Participants need to be able to swallow tablets and must have adequate blood cell counts, meaning their bone marrow has started working properly after the transplant. The study will test venetoclax at different dose levels to find the highest dose that patients can tolerate without experiencing unacceptable side effects.

During the study, participants will receive venetoclax tablets for up to 56 days. Doctors will monitor how well the treatment works and watch for any side effects. They will check whether the acute graft-versus-host disease improves or gets worse, and they will look at survival rates and other complications. The study will also examine blood samples and tissue samples to understand how venetoclax affects the cells that cause graft-versus-host disease. Researchers will assess the quality of life of participants and measure their fatigue levels throughout the treatment period.

Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies

Wed, 29 Apr 2026 14:59:37 +0000

This clinical trial is focused on evaluating the long-term safety of treatments for patients who have previously participated in studies involving the medication ruxolitinib, either alone or in combination with other drugs. Ruxolitinib is a medication used to treat certain types of blood disorders. In this study, it may be combined with other medications such as panobinostat, siremadlin (also known as HDM201), or rineterkib. The purpose of the study is to gather information on the safety of these treatments over a longer period.

Participants in this study will continue their treatment with ruxolitinib or its combinations as they have been doing in their previous studies. The study will monitor the frequency and severity of any side effects or adverse events that occur during the treatment. This information will help researchers understand the long-term safety of these medications and their combinations.

The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. It is conducted at multiple centers, allowing for a diverse group of participants. The study aims to provide valuable data on the safety of these treatments, which can benefit future patients who may receive these medications. Participants will be assessed regularly to determine any clinical benefits they may experience from the continued treatment.

Study Comparing Methylprednisolone and Methoxsalen for Treating Grade II Acute Graft-Versus-Host Disease in Adult Stem Cell Transplant Patients

Wed, 29 Apr 2026 14:47:35 +0000

This clinical trial is focused on studying a condition known as Grade II acute graft-versus-host disease (GVHD), which can occur after a patient receives a stem cell transplant from a donor. This condition often affects the skin and may also involve the upper part of the digestive system. The study aims to compare two different treatment approaches for this condition. One group of patients will receive treatment with corticosteroids alone, while the other group will receive a combination of corticosteroids and a procedure called extracorporeal photopheresis (ECP). ECP is a process where blood is treated outside the body to help manage the disease.

The trial will involve the use of several medications. SOLUMEDROL, which contains the active ingredient methylprednisolone hemisuccinate, and CORTANCYL, which contains prednisone, are both corticosteroids used in the study. Additionally, Uvadex, containing methoxsalen, is used in conjunction with the ECP procedure. Another medication, Noxafil, which contains posaconazole, is also part of the study. The purpose of the study is to determine which treatment approach is more effective in preventing treatment failure, which means the disease does not worsen or require additional treatment, over a period of six months.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for several months, during which patients will receive their assigned treatment and be monitored for any changes in their condition. The goal is to see how well each treatment works in managing the symptoms of acute GVHD and to assess the overall health and quality of life of the participants. The study will also track any side effects or complications that may arise during the treatment period.